Introduction
Cardiac transplantation is an established treatment for end-stage cardiac failure. However, longer recipient survival following cardiac transplantation has led to new medical problems, 1 including hypertension and renal impairment. Brain natriuretic peptide (BNP) and atrial natriuretic peptide (ANP) are produced in the heart and are increased in patients with hypertension, 2 and/or impaired renal function. 3 Additionally, BNP and ANP increase with dietary sodium loading, 4 indicating that volume expansion, as well as blood pressure, may be a stimuli for release of these two peptides into the circulation. Since many cardiac transplant recipients have increased blood pressures, and/or renal impairment, we have investigated plasma levels of BNP and ANP in cardiac transplant recipients compared with healthy subjects. Furthermore, circulating forms of BNP and ANP in human plasma were investigated using gel filtration chromatography of extracted plasma from cardiac transplant recipients.
Subjects and methods
Twenty healthy subjects (6 female, 14 male) mean age 33 years were studied on their normal sodium intake. Supine blood pressure (mm Hg, mean ± s.e.m.) was 126 ± 3/76 ± 2.
Twelve orthotopic cardiac transplant recipients (all male) mean age 53 years. Supine blood pressure 152 ± 7/92 ± 4 mm Hg and plasma creatinine 148.1 ± 12.4 mol/l. These patients were on immunosuppressive therapy with cyclosporin A. Subjects gave informed consent to the studies which were approved by the local hospital ethical committee.
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Assay for BNP and ANP
Blood for ANP, BNP and other measurements were collected with subjects sitting upright. Plasma BNP and ANP were measured by radioimmunoassay for BNP (1-32) and ANP (99-126) after extraction as described previously.
3 BNP and ANP levels are in pmol/l.
Gel filtration of extracted plasma
Gel filtration was undertaken on a column of 30 × 1.6 cm (internal diameter) using sephadex G50 and 1 ml fractions were collected. The column was calibrated using synthetic human BNP (1-32) and ANP (99-126) standards. Pooled plasma from cardiac transplant recipients (48 ml) was extracted on Sep-Pak cartridges, reconstituted in a 0.5 ml volume of assay buffer 3 and loaded onto the column. Fractions collected were tested for immunoreactivity using the BNP and ANP radioimmunoassays. 
Statistical analysis
Significant differences between groups were detected using unpaired t-tests; non-parametric tests were also used in the presence of unequal group variance. Group values are mean ± s.e.m.; a twotailed P value of Ͻ0.05 was taken as significant.
Results

Plasma BNP and ANP
In 20 healthy subjects plasma levels of BNP and ANP were 1.0 ± 0.1 and 2.9 ± 0.3 pmol/l, respectively. Plasma ANP was approximately 2.9 ± 0.3-fold higher than BNP (Figure 1 ).
In the 12 cardiac transplant recipients plasma BNP and ANP were similar with values of 18.6 ± 4.9 and 18.8 ± 4.0 pmol/l respectively (Figure 1) . However, BNP and ANP were significantly raised in the cardiac transplant recipients (P Ͻ 0.001) compared with the healthy subjects. 
Gel filtration of extracted plasma
After gel filtration of extracted plasma from cardiac transplant recipients BNP immunoreactivity occurred as two separate and distinct peaks (Figure 2 ), a high molecular weight peak and a low molecular weight peak which corresponded to the elution volume of synthetic human BNP (1-32) standard. ANP measurement on the same fractions revealed a single immunoreactive peak corresponding to the elution volume of synthetic human ANP (99-126) standard (Figure 2) .
Discussion
These studies demonstrate that in healthy subjects ANP circulates at higher concentrations than BNP (Figure 1) , and that both BNP and ANP are increased substantially in the cardiac transplant group compared with the healthy subjects. However, in cardiac transplant recipients the plasma levels of both BNP and ANP were equivalent, indicating increased release of BNP in relation to ANP into the circulation in these patients. The precise reasons for these high levels of BNP and ANP in cardiac transplant recipients are not clear, but could be due to a combination of factors, including higher age and blood pressures, which are associated with increased plasma BNP and ANP. 2 Furthermore, decreased clearance of the peptides by the kidney may have further elevated the plasma levels, since these patients had slightly increased plasma creatinine, and both BNP and ANP are elevated in patients with decreased renal function. 3 Although plasma levels of BNP and ANP were similar in the cardiac transplant recipients, there were clear differences in the molecular circulating forms present in human plasma (Figure 2 ). BNP immunoreactivity consisted of two forms, a low molecular weight form corresponding to BNP (1-32) and a high molecular weight form (Figure 2 ), possibly the complete prohormone proBNP (1-108) with the 32 amino acid peptide BNP (1-32) at its carboxyl-terminal end. In contrast, all of the immunoreactivity for ANP occurred as a low molecular weight form corresponding to ANP (99-126).
